california glp 1 coverage Over half a million Californians could lose access to the hugely popular -1 weight loss drugs starting Jan. 1, 2026, after the state government decided to deny some Medi-Cal for the GLP-1 coverage for obesity treatment

Targeting Wnt/-Catenin pathway for developing therapies for hair loss

Each pathway targets specific aspects of vascular and cellular integrity, contributing to the overall protection and remodeling of the retinal vasculature in conditions like DR and ischemic retinal diseases (see Figure 5)

This is the second time Pfizer has pulled back on danuglipron, with the company previously discontinuing a twice-daily version in late 2023 due to tolerability concerns

Suppress inappropriate glucagon secretion: reduce hepatic glucose output when blood sugar is high

In-person consultations are available at 5375 S Fort Apache Rd, Suites 102 & 103, Summerlin, Las Vegas, NV 89148

Higher doses tended to result in more weight loss compared to placebo